In liver cancer cell lines, MAPT expression was negatively associated with resistance to bleomycin, a DNA-damaging drug approved for squamous cell head and neck cancer, Hodgkin’s lymphoma, and testicular carcinoma55. The gene discussed is MAPT; the disease is liver cancer.